Consortium for Metabonomic Toxicology (COMET)


At a Glance
  • Status: Completed Consortium
  • Year Launched: 2003
  • Initiating Organization: Imperial College
  • Initiator Type: Academia
  • No disease focus
  • Location: Europe

Abstract

The Consortium for Metabonomic Toxicology (COMET) was formed by five major pharmaceutical companies and Imperial College London, UK. Its main objectives were to assess methodologies, generate a metabonomic database using nuclear magnetic resonance (NMR) spectroscopy, and build a predictive expert system for target organ toxicity.

Mission

COMET’s aims included the following:

Consortium History

COMET completed study of 147 of 150 compounds (25 per company) selected by the Steering Committee that would provide robust predictive models that covered an extensive range of metabolic space.

Structure & Governance

A Steering Committee with personnel from each company and Imperial College oversaw the project.

Financing

The project was funded for three years.

Impact/Accomplishment

The consortium completed 147 studies. NMR spectra, associated meta-data, and all data generated by the project were organized as a relational database. The database was organized in a hierarchy descending from each of the 147 studies as the root element.

Sponsors & Partners

Bristol-Myers Squibb

Eli Lilly & Co.

Hoffman-La Roche

Imperial College London

NovoNordisk

Pfizer, Inc.

The Pharmacia Corporation (now part of Pfizer)


Last Updated: 04/14/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.